[ibd-display-video id=2102289 width=50 float=left autostart=true] This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an 80 or higher RS Rating as they begin their largest climbs. See if Flexion Therapeutics can continue to rebound and clear that threshold.
Flexion Therapeutics is not currently showing a potential buy point. See if the stock goes on to build a promising consolidation that could kick off a new price move.
The company showed -44% earnings growth in the latest quarterly report. Revenue rose 0%.
Flexion Therapeutics earns the No. 200 rank among its peers in the Medical-Biomed/Biotech industry group. Celgene ( CELG ), Corcept Therapeutics ( CORT ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.